For routine prophylaxis in patients 12 years and older with hemophilia A or B without inhibitors

HYMPAVZI™

marstacimab-hncq

injection | 150 mg/mL



Pen is not actual size. Read full Instructions for Use.

This moment belongs to me.

When it all clicks, that's HYMPAVZI.

• Prefilled • Fixed dose* • Once weekly

*Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose consisting of 1 or 2 injections as prescribed by your healthcare provider. If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

What is HYMPAVZI?

HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.

It is not known if HYMPAVZI is safe and effective in children younger than 12 years old.

IMPORTANT SAFETY INFORMATION

Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products (products that help blood clot but work in a different way than HYMPAVZI). You may need to use factor VIII or factor IX medicines to treat episodes of breakthrough bleeding during treatment with HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when to use factor VIII or factor IX medicines and the prescribed dose during your treatment with HYMPAVZI.

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

You know that moment when everything clicks?
That moment is now.

Once-weekly HYMPAVZI is a subcutaneous prophylactic treatment for hemophilia A and B without inhibitors that comes in a fixed-dose,* prefilled pen.

*Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose consisting of 1 or 2 injections as prescribed by your healthcare provider. If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

What is HYMPAVZI?

HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.

It is not known if HYMPAVZI is safe and effective in children younger than 12 years old.

IMPORTANT SAFETY INFORMATION

Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products (products that help blood clot but work in a different way than HYMPAVZI). You may need to use factor VIII or factor IX medicines to treat episodes of breakthrough bleeding during treatment with HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when to use factor VIII or factor IX medicines and the prescribed dose during your treatment with HYMPAVZI.

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

Dive In.

✔ Proven bleed protection* ✔ Innovative treatment approach ✔ Once-weekly prefilled pen

Use this brochure to learn more about HYMPAVZI.

Underlined terms are defined in the glossary on page 21.

This brochure is not meant to replace the advice of your healthcare team.

*In the BASIS phase 3 study, the primary objective was to measure the annualized bleed rate (ABR) of treated bleeds vs on-demand factor-based treatment and vs factor-based prophylaxis after 12 months on HYMPAVZI. 92% reduction in treated bleeds on HYMPAVZI compared with on-demand factor-based treatment (3.18 ABR vs 38.00 ABR). 35% reduction in treated bleeds on HYMPAVZI compared with routine prophylaxis treatment (5.08 ABR vs 7.85 ABR).

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

What is HYMPAVZI?

A treatment option designed to fit your lifestyle.

HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.

Proven bleed protection* shown in the BASIS phase 3 study to help reduce:

- **Treated bleeds**
- **Total bleeds**
- **Spontaneous bleeds**
- **Joint bleeds**
- **Target joint bleeds**

See clinical study data below. See pages 10 and 11 for detailed efficacy information.

Once-weekly, fixed-dose, prefilled pen†



Pen is not actual size. Read full Instructions for Use.

Clinical study data

*In the BASIS phase 3 study, the primary objective was to measure the annualized bleed rate (ABR) of treated bleeds vs on-demand factor-based treatment and vs factor-based prophylaxis after 12 months on HYMPAVZI. 92% reduction in treated bleeds on HYMPAVZI compared with on-demand factor-based treatment (3.18 ABR vs 38.00 ABR). 35% reduction in treated bleeds on HYMPAVZI compared with routine prophylaxis treatment (5.08 ABR vs 7.85 ABR). Secondary objectives measured the ABR of treated joint bleeds, treated target joint bleeds, treated spontaneous bleeds, and total bleeds. 91% reduction in joint bleeds on HYMPAVZI compared with on-demand factor-based treatment (2.83 ABR vs 32.86 ABR). 27% reduction in joint bleeds on HYMPAVZI compared with routine prophylaxis treatment (4.13 ABR vs 5.66 ABR). 92% reduction in target joint bleeds on HYMPAVZI compared with on-demand factor-based treatment (1.84 ABR vs 23.18 ABR). 25% reduction in target joint bleeds on HYMPAVZI compared with routine prophylaxis treatment (2.51 ABR vs 3.36 ABR). 92% reduction in spontaneous bleeds on HYMPAVZI compared with on-demand factor-based treatment (2.44 vs 30.93 ABR). 35% reduction in spontaneous bleeds on HYMPAVZI compared with routine prophylaxis treatment (3.78 ABR vs 5.86). 85% reduction in total bleeds on HYMPAVZI compared with on-demand factor-based treatment (7.39 ABR vs 47.76 ABR). 32% reduction in total bleeds on HYMPAVZI compared with routine prophylaxis treatment (5.97 ABR vs 8.84 ABR). Individual results may vary.

†Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose consisting of 1 or 2 injections as prescribed by your healthcare provider. If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

IMPORTANT SAFETY INFORMATION (cont'd)

Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you:

- have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery.
- have a severe short-term (acute) illness such as an infection or injury.
- are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby.

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

NO LENGTHY PREP
HYMPAVZI pen comes ready to use. No mixing, measuring, or reconstituting required.

READY TO USE
Prefilled, fixed-dose* pen.

LESS INVASIVE DELIVERY
Subcutaneous HYMPAVZI is injected under the skin, not into a vein.

NO VISIBLE NEEDLE
Once the cap is twisted off, the needle cover stays inside the cap.

FLEXIBLE STORAGE AND PORTABILITY
HYMPAVZI can be stored in the refrigerator until expiration, and at room temperature in the original carton for up to 7 days.

There's even more to the HYMPAVZI story. Keep reading. >>

The HYMPAVZI pen is stored in the refrigerator (36°F to 46°F) until expiration. It can also be removed from the refrigerator and stored at room temperature (up to 86°F) in the original carton for up to 1 week. Once reaching room temperature, HYMPAVZI must not be returned to refrigerated storage and should be used or discarded. Keep the HYMPAVZI pen out of direct sunlight. Do not freeze or shake.

*Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose consisting of 1 or 2 injections as prescribed by your healthcare provider. If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

HYMPAVZI in action

HYMPAVZI is designed to help restore balance in the clotting process by targeting an anticlotting factor (anticoagulant) in the body called tissue factor pathway inhibitor (TFPI).

In someone without hemophilia, anticlotting factors (anticoagulants) and clotting factors (procoagulants) are balanced so the body can clot when needed without causing too much clotting or too much bleeding. Think of this balance as a scale that represents the balance of anticlotting factors and clotting factors in the body.



IMPORTANT SAFETY INFORMATION (cont'd)

Females who are able to become pregnant:

- Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI.
- You should use effective birth control (contraception) during treatment with HYMPAVZI and for at least 2 months after the last dose of HYMPAVZI.
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI.

• are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk.

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

How HYMPAVZI is thought to work in 3 simple steps



- In people with hemophilia, there is a lack of clotting factors causing an imbalance.
- This can make it difficult to stop bleeding.



HYMPAVZI uses an innovative approach that may help **restore this balance** by targeting TFPI to decrease anticlotting factor activity.

- **Blocking the activity of TFPI** increases the tendency to develop thrombin, which may improve clotting function.
- This could potentially **help the body prevent or reduce the frequency of bleeding episodes.**

APC=activated protein C; AT=antithrombin; TFPI=tissue factor pathway inhibitor. These do not represent all of the anticlotting and clotting factors in the body.

If you have more questions about how HYMPAVZI works, use page 20 to write them down to ask your doctor later.

How was HYMPAVZI studied?

Study objectives

Primary objective

The primary objective of the trial focused on the annualized bleed rate (ABR) of treated bleeds during treatment with HYMPAVZI, compared to the mean ABR of factor-based on-demand and routine prophylactic treatment in patients.

Mean ABR: The average number of bleeds a person has in one year.

Secondary objectives

In people with hemophilia treated with HYMPAVZI:

- Number of treated bleeds that occur in all joints and in target joints during the 12-month active treatment phase
- Number of treated spontaneous bleeds (bleeds that occur from no known cause) during the 12-month active treatment phase
- Number of total bleeds (treated and untreated) during the 12-month active treatment phase

Trial overview

The 18-month clinical trial consisted of a **6-month observational period** (when the patients were taking either "on-demand" factor replacement treatment or routine factor-based prophylactic treatment) followed by a **12-month active treatment period** with HYMPAVZI.

Participants

116 adults and adolescent male participants ages 12+, with severe hemophilia A or B without inhibitors

=

83 routine factor-based prophylaxis participants

+

33 on-demand factor-based treatment participants

IMPORTANT SAFETY INFORMATION (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

Right here. Right now.

HYMPAVZI delivered proven bleed protection

Study results from the phase 3 clinical trial

Study Results*

When compared to on-demand factor-based treatment and prophylactic factor-based treatment, HYMPAVZI demonstrated the following in the BASIS phase 3 study:

Primary objective — 12-month active treatment period

ABR of treated bleeds with HYMPAVZI:

Fewer treated bleeds

HYMPAVZI reduced the number of treated bleeding episodes

92% **lower** than on-demand (HYMPAVZI: 3.18 ABR vs On-demand: 38.00 ABR)

35% **lower** than routine prophylaxis (HYMPAVZI: 5.08 ABR vs Prophylaxis: 7.85 ABR)

*The primary objective of the trial focused on the annualized bleed rate (ABR) of treated bleeds during treatment with HYMPAVZI, compared to the mean ABR of factor-based on-demand and routine prophylactic treatment in patients. The secondary objectives of the study included evaluation of HYMPAVZI prophylaxis (compared with on-demand and routine prophylactic factor-based treatment) based on the incidences of treated joint bleeds, treated target joint bleeds, treated spontaneous bleeds, and total bleeds.

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of HYMPAVZI?

HYMPAVZI may cause serious side effects, including:

- **blood clots (thromboembolic events).** HYMPAVZI may increase the risk for your blood to clot. Blood clots may form in blood vessels in your arm, leg, lung, or head and can be life-threatening. Get medical help right away if you develop any of these signs or symptoms of blood clots: swelling or pain in arms or legs, redness or discoloration in your arms or legs, shortness of breath, pain in chest or upper back, fast heart rate, cough up blood, feel faint, headache, numbness in your face, eye pain or swelling, or trouble seeing

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

Additional study results

Secondary objectives

Fewer joint bleeds

ABR of joint bleeds with HYMPAVZI:

91% **lower** than on-demand (HYMPAVZI: 2.83 ABR vs On-demand: 32.86 ABR)

27% **lower** than routine prophylaxis (HYMPAVZI: 4.13 ABR vs Prophylaxis: 5.66 ABR)

Fewer target joint bleeds

If a joint had 3+ bleeds in a span of 6 months, it's considered a target joint.

ABR of target joint bleeds with HYMPAVZI:

92% **lower** than on-demand (HYMPAVZI: 1.84 ABR vs On-demand: 23.18 ABR)

25% **lower** than routine prophylaxis (HYMPAVZI: 2.51 ABR vs Prophylaxis: 3.36 ABR)

Fewer spontaneous bleeds

ABR of spontaneous bleeds with HYMPAVZI:

92% **lower** than on-demand (HYMPAVZI 2.44 ABR vs On-demand: 30.93 ABR)

35% **lower** than routine prophylaxis (HYMPAVZI: 3.78 ABR vs Prophylaxis: 5.86 ABR)

Fewer total bleeds

ABR of total bleeds with HYMPAVZI:

85% **lower** than on-demand (HYMPAVZI: 7.39 ABR vs On-demand: 47.76 ABR)

32% lower than routine prophylaxis (HYMPAVZI: 5.97 ABR vs Prophylaxis: 8.84 ABR)

Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products to treat breakthrough bleeds while using HYMPAVZI.*

*You may need to use factor VIII or factor IX products to treat episodes of breakthrough bleeding while using HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when and how to use factor VIII or factor IX products while using HYMPAVZI. Individual results may vary.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

Here's safety information you should know

- HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist, and may increase the risk of thromboembolic complications.
- HYMPAVZI may cause hypersensitivity reactions (including, but not limited to urticaria [hives] and pruritus [itching]). If you develop a hypersensitivity reaction during treatment with HYMPAVZI, stop using HYMPAVZI and get medical help right away.
- HYMPAVZI may cause fetal harm when administered to a pregnant woman. Women who are able to bear children are advised to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

You may need to use factor VIII or factor IX products to treat episodes of breakthrough bleeding while using HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when and how to use factor VIII or factor IX products while using HYMPAVZI. Individual results may vary.

From the BASIS Clinical Trial:

A serious adverse reaction of peripheral swelling occurred in one patient.

The most common side effects reported in ≥3% of patients treated with HYMPAVZI were*:

Adverse Reactions (N=116)	Number of Patients, n (%)
Injection site reaction	11 (9)
Headache	8 (7)
Pruritus (itching)	4 (3)

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of HYMPAVZI?

HYMPAVZI may cause serious side effects, including (cont'd):

- **allergic reactions.** Allergic reactions, including rash and itching have happened in people treated with HYMPAVZI. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction: swelling of your face, lips, mouth, or tongue; trouble breathing; wheezing; dizziness or fainting; fast heartbeat or pounding in your chest; sweating

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

The most common side effects reported in ≥3% of patients treated with HYMPAVZI were*:

- Injection site reaction
- Headache
- Pruritus (itching)

HYMPAVZI may cause serious side effects, including:

- **blood clots (thromboembolic events).** HYMPAVZI may increase the risk for your blood to clot. Blood clots may form in blood vessels in your arm, leg, lung, or head and can be life-threatening. Get medical help right away if you develop any of these signs or symptoms of blood clots:
  - swelling or pain in arms or legs
  - redness or discoloration in your arms or legs
  - shortness of breath
  - pain in chest or upper back
  - fast heart rate
  - cough up blood
  - feel faint
  - headache
  - numbness in your face
  - eye pain or swelling
  - trouble seeing

- **allergic reactions.** Allergic reactions, including rash and itching have happened in people treated with HYMPAVZI. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction:
  - swelling of your face, lips, mouth, or tongue
  - trouble breathing
  - wheezing
  - dizziness or fainting
  - fast heartbeat or pounding in your chest
  - sweating

These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

*These were the most common side effects reported during the 12-month active treatment period of the phase 3 BASIS study. A serious adverse reaction of peripheral swelling occurred in one patient. HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist, and may increase the risk of thromboembolic complications. HYMPAVZI has not been studied in patients with a history of previous thromboembolic events.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

Ready to embrace the moment?
It starts with a click.



Pen is not actual size. Read full Instructions for Use.

SUBCUTANEOUS DELIVERY

HYMPAVZI is injected under the skin, not into a vein.

FIXED DOSE,* PREFILLED PEN

The same dose comes in every pen, so you don't need to mix or measure.

FLEXIBLE STORAGE

HYMPAVZI can be stored in the refrigerator until expiration, and at room temperature in the original carton for up to 7 days.†

*Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose consisting of 1 or 2 injections as prescribed by your healthcare provider. If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

†HYMPAVZI should not be returned to the refrigerator once it has been taken out.

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects of HYMPAVZI are injection site reactions, headache, and itching.

These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

The HYMPAVZI prefilled pen
No measuring. No mixing. No reconstitution.

Explore all the features of the prefilled pen. With a hidden needle and a ready-to-use design, the HYMPAVZI prefilled pen is made to fit your lifestyle.

Cap

1

Once the cap is twisted off, the needle cover will stay inside the cap.

Hidden needle

2

With its design and autoinjector delivery, you can inject HYMPAVZI into your thigh or abdomen. HYMPAVZI may also be injected into your buttocks by a healthcare provider or caregiver only. HYMPAVZI should not be injected into a vein.

Window

3

The HYMPAVZI pen comes prefilled and ready to use. This window also lets you see when you've received the full dose during the injection process.

Fixed dose*

4

One week after your loading dose, you take the same dose (150 or 300 mg) every week.

How to store HYMPAVZI

It's important to store your HYMPAVZI medication properly so it stays effective and safe for you to use.

- The HYMPAVZI pen is stored in the refrigerator (36°F to 46°F) until expiration.
- It can also be removed from the refrigerator and stored at room temperature (up to 86°F) in the original carton for up to 1 week.
- Once reaching room temperature, HYMPAVZI must not be returned to refrigerated storage and should be used or discarded.†
- Keep the HYMPAVZI pen out of direct sunlight. Do not freeze or shake.

*Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose consisting of 1 or 2 injections as prescribed by your healthcare provider. If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

†HYMPAVZI should not be returned to the refrigerator once it has been taken out.

Excited for his future.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

How to take HYMPAVZI

Once-weekly dosing, designed to fit your schedule.

HYMPAVZI is intended for use under the guidance of a healthcare provider. After proper demonstration in subcutaneous injection technique, you may self-inject, or a caregiver may administer HYMPAVZI, if a healthcare provider determines that it is appropriate.

Once-weekly dosing, designed to fit your schedule

Day 1: loading dose
The first dose is 300 mg
(two 150 mg pens)

Day 8: start once-weekly maintenance dose
Once-weekly dose is 150 mg or 300 mg
as prescribed by your healthcare provider
(one 150 mg or two 150 mg pens)

After your first dose of 300 mg (2 subcutaneous injections) you need to inject HYMPAVZI once a week. In the following weeks, you can take your dose the same day each week at any time of day. Each prefilled pen has a fixed dose of 150 mg. Change (rotate) the injection site each time you give yourself an injection of HYMPAVZI and away from any other medicine given under your skin. You may use the same area of your body but be sure to choose a different injection site in that area.

For people weighing 50 kg or more, their healthcare provider may change the maintenance dose to 300 mg weekly if the 150 mg maintenance dose is not enough to prevent bleeding events.

Click here or scan the QR code to watch a video to see how to inject HYMPAVZI step by step.

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

We're here to help
so you can focus on what matters most.

Support for HYMPAVZI from Pfizer Hemophilia Connect

When HYMPAVZI is prescribed by your doctor, Pfizer may provide you with information about insurance coverage and reimbursement support, as well as educational resources to help along the treatment journey.

Pfizer Hemophilia Connect provides patients prescribed HYMPAVZI with:
- Access to a Patient Case Manager to answer questions about your insurance coverage
- Information about available patient support resources from Pfizer, including eligibility requirements
- Educational resources about HYMPAVZI and hemophilia

Call to learn more about available programs or to enroll in Pfizer Hemophilia Connect:
Monday through Friday, 8 AM – 6 PM ET at 1-888-733-2030

Patient Case Managers (PCMs)
Offer live, one-on-one, non-medical support for patients who are prescribed HYMPAVZI. Once enrolled in Pfizer Hemophilia Connect, your Pfizer PCM can provide information about insurance coverage and reimbursement and financial assistance programs, if you are eligible.

Click here or scan this QR code to get details about all of our support programs at HYMPAVZI.com.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

Patient Support

Find education on insurance coverage–and patient support, if eligible, for HYMPAVZI. Get the answers you need to navigate your next steps.

HYMPAVZI Co-Pay Savings Program*

Eligible, commercially insured patients may pay as little as $0 in out-of-pocket costs, with a maximum benefit of $15,000 per calendar year, with the HYMPAVZI Co-Pay Savings Program. Terms and Conditions are below. Enrollment in Pfizer Hemophilia Connect is not required for this program.

Insurance Coverage Support

A Pfizer Patient Case Manager (PCM) at Pfizer Hemophilia Connect provides personalized, live support to explain the insurance coverage process for HYMPAVZI, as well as identify potential financial assistance based on eligibility. Enroll in Pfizer Hemophilia Connect to request support from a dedicated PCM.

Connect to educational support

Our commitment to the community includes Pfizer Patient Navigators (PNs)
PNs can connect you with advocacy groups, provide educational resources about living with hemophilia, and answer questions about Pfizer programs. To connect to a PN, please visit TogetherForRare.com.

HYMPAVZI Helpline live phone support
Call 1-888 HYMPAV-Z (1-888-496-7289) for more information.

*FULL CO-PAY SAVINGS PROGRAM TERMS AND CONDITIONS
By using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as "La Reforma de Salud"). Patient must have private insurance with coverage for HYMPAVZI™. Offer is not valid for cash paying patients. The value of this co-pay card is limited to $15,000 per calendar year or the amount of your co-pay over 1 year, whichever is less. This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs. You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards. This co-pay card is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third party insurance. This co-pay card is not valid where prohibited by law. The benefit under the co-pay card program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either. Co-pay card cannot be combined with any other external savings, free trial, or similar offer for the specified prescription (including any program offered by a third-party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as "accumulator" or "maximizer" programs). Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the co-pay card program. Co-pay card will be accepted only at participating pharmacies. This co-pay card is not health insurance. Offer good only in the U.S. and Puerto Rico. Co-pay card is limited to 1 per person during this offering period and is not transferable. No other purchase is necessary. Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer's programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you. Pfizer reserves the right to rescind, revoke or amend this offer without notice. Offer expires 12/31/2025. No membership fees.

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

Questions for your healthcare provider
Could HYMPAVZI be the right option for you?

How is HYMPAVZI treatment different from others I have taken?

How can HYMPAVZI fit in with my lifestyle or treatment goals?

Will HYMPAVZI replace my other hemophilia treatment(s)?

Based on my medical history, do you think HYMPAVZI is appropriate for me?

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

Glossary

Anticoagulants
Proteins that promote blood flow

BASIS
A phase 3 study evaluating the efficacy and safety of HYMPAVZI

Mean ABR
The average number of bleeds a person has in one year

Primary objective
The main goal of the study

Procoagulants
Proteins that promote clotting

Prophylactic
A treatment given on a regular basis to prevent disease

Pruritus
Itching

Secondary objective
Additional goals of a study that support the main goal

Subcutaneous
Injections given under the skin

Thromboembolic
Due to blood clot(s)

Thromboembolic complications
Serious medical conditions caused by a blood clot

Tissue factor pathway inhibitor (TFPI)
A naturally occurring anticoagulation protein that prevents clotting

Urticaria
Hives

What is HYMPAVZI?
HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.

It is not known if HYMPAVZI is safe and effective in children younger than 12 years old.

IMPORTANT SAFETY INFORMATION

Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products (products that help blood clot but work in a different way than HYMPAVZI). You may need to use factor VIII or factor IX medicines to treat episodes of breakthrough bleeding during treatment with HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when to use factor VIII or factor IX medicines and the prescribed dose during your treatment with HYMPAVZI.

Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you:
- have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery.
- have a severe short-term (acute) illness such as an infection or injury.
- are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby.

  Females who are able to become pregnant:
  - Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI.
  - You should use effective birth control (contraception) during treatment with HYMPAVZI and for at least 2 months after the last dose of HYMPAVZI.
  - Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI.
- are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of HYMPAVZI?
HYMPAVZI may cause serious side effects, including:
- **blood clots (thromboembolic events).** HYMPAVZI may increase the risk for your blood to clot. Blood clots may form in blood vessels in your arm, leg, lung, or head and can be life-threatening. Get medical help right away if you develop any of these signs or symptoms of blood clots:
  - swelling or pain in arms or legs
  - redness or discoloration in your arms or legs
  - shortness of breath
  - pain in chest or upper back
  - fast heart rate
  - cough up blood
  - feel faint
  - headache
  - numbness in your face
  - eye pain or swelling
  - trouble seeing

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

- **allergic reactions.** Allergic reactions, including rash and itching have happened in people treated with HYMPAVZI. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction:
  - swelling of your face, lips, mouth, or tongue
  - trouble breathing
  - wheezing
  - dizziness or fainting
  - fast heartbeat or pounding in your chest
  - sweating

The most common side effects of HYMPAVZI are injection site reactions, headache, and itching.

These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



Pen is not actual size. Read full Instructions for Use.

Please see full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

For routine prophylaxis in patients 12 years and older with hemophilia A or B without inhibitors

HYMPAVZI™

marstacimab-hncq

injection | 150 mg/mL

Once-weekly HYMPAVZI is a subcutaneous prophylactic treatment for hemophilia A and B without inhibitors that comes in a fixed-dose,* prefilled pen.

It starts with a click.

The next move is yours.

Talk with your healthcare provider.

Pfizer: Here For Hemophilia For Over 25 Years

Pfizer continues to support the hemophilia community, remaining committed to the research and having helped develop innovative treatment options across severities for both hemophilia A and B. Learn more at **HereForHemophilia.com**.

HYMPAVZI Educational Resources Sent Right to Your Inbox

Click here or scan the QR Code to sign up at **HYMPAVZI.com/sign-up** to get emails with information and educational resources to help you get started.

*Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose consisting of 1 or 2 injections as prescribed by your healthcare provider. If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

Please see Important Safety Information throughout and on pages 22 and 23, and full Prescribing Information, including Patient Information and Instructions for Use, at www.HYMPAVZI.com.

Pfizer